Audiencias - Año 2022 - Bárbara Vallejos - Audiencia AC007AW1069658

Información General

Asistentes

Nombre completo	Calidad	Trabaja para	Representa a
Woonha Lee (SK bioscience)	Gestor de intereses		Woonha Lee

Materias tratadas

Celebración, modificación o terminación a cualquier título, de contratos que realicen los sujetos pasivos y que sean necesarios para su funcionamiento.

Especificación materia tratada

Dear Mr. Rodrigo Yañez, Feliz Año Nuevo, and I hope this email finds you well. I am Woonha from the Business Development team, working with Jin, Ikjung, and John for global business. Thank you for CENABAST’s continuous interest in potential cooperation with SK bioscience. Today, I would like introduce our Covid-19 program to discuss expansion of our collaboration in Covid-19 field. As you may know, we are developing a novel Covid-19 vaccine under global collaboration with partners, including CEPI’s utmost support. SK’s product is in a late stage of multi-national phase 3 clinical study based on very promising phase 1/2 result; (100% neutralization antibody generation against Covid-19, 100% seroconversion rate and cross-neutralization for Delta variant), expecting to have final regulatory approval including EMA/WHO in the middle of this year. The vaccine is a recombinant-protein subunit vaccine based on a novel two-component self-assembling nanoparticle technology developed with the University of Washington targeting receptor binding domain (RBD) of the spike protein of SARS-CoV-2, and one of the best adjuvants, GSK’s AS03 is used. Under the feature of liquid, protein subunit, and cell culture platform, there will be many advantages such as thermostability (2-8°C degree), favorable price, high yield, etc. Recent results of NHP (non-human primate) show cross-neutralization protecting against not only Wuhan but also other variants such as Delta or even Omicron. In addition to pivotal phase 3 clinical trial that includes Caucasian subjects, series of studies such as homo/heterologous booster studies are on-going or planned to be started sooner or later. Furthermore, we are developing an Omicron variant vaccine. I’ve heard that there are more and more breakthrough cases in Chile due to the rapidly spreading Omicron variant. Thus, we would like to discuss the opportunities to support Chilean public health. Although the first step for this sophisticated product would be simple export/import, it would be much appreciated if we can get your help and advice to start the discussion with CENABAST for the advance purchase of SK’s Covid-19 vaccine. If you are not the right contact, could you kindly connect me with the responsible person on this subject? We can also set up a short call if needed, and I look forward to hearing back from you soon. Best regards, Woonha Lee (woonha.lee@sk.com) SK bioscience / Global Business Development Department Representantes de SK Bioscience presenta la farmacéutica y los avances de la vacuna SKYCovione, la cual aún está a la espera de los resultados de Fase 3. En la reunión participaron las asesoras Bárbara Vallejos y Camila Cabrera.